RBC Capital analyst Gregory Renza maintained a Buy rating on Avalo Therapeutics (AVTX – Research Report) on November 7 and set a price target of $17.00. The company’s shares closed yesterday at $6.10.
Renza covers the Healthcare sector, focusing on stocks such as Jazz Pharmaceuticals, Seagen, and Prometheus Biosciences. According to TipRanks, Renza has an average return of -2.3% and a 33.18% success rate on recommended stocks.
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Avalo Therapeutics with a $10.00 average price target, implying a 63.93% upside from current levels. In a report released on November 9, Oppenheimer also maintained a Buy rating on the stock with a $10.00 price target.
See Insiders’ Hot Stocks on TipRanks >>
Based on Avalo Therapeutics’ latest earnings release for the quarter ending June 30, the company reported a quarterly revenue of $1.03 million and a GAAP net loss of $12.99 million. In comparison, last year the company earned a revenue of $3.36 million and had a GAAP net loss of $17.11 million
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Cerecor, Inc. is a clinical stage biopharmaceutical company focuses in medical development. It involves in the discovery, manufacture and commercialization of prescription for neurological and psychiatric disorders. It products include CERC-301, CERC-501, CERC-611, and CERC-406. The company was founded by Blake M. Paterson, Isaac Blech, Barbara S. Slusher and Solomon H. Snyder on January 31, 2011 and is headquartered in Baltimore, MD.
Read More on AVTX:
- Avalo Therapeutics price target lowered to $10 from $17 at Oppenheimer
- Avalo Reports Third Quarter 2022 Financial Results and Provides Business Updates
- Avalo Therapeutics announces upcoming updates, milestones
- Avalo Therapeutics reports Q3 EPS 34c vs ($2.08) last year
- Avalo sells economic rights to previously out-licensed assets for $5M
